The long-lasting protective effect of dexrazoxane (ADR-529) against doxorubicin- and epirubicin-induced cardiotoxicity was evaluated in the multiple-dose 35-wk rat model. Groups of 36 male Sprague-Dawley rats were given ADR-529 30 min before administration of cardiotoxic doses of doxorubicin (1 mg/kg/wk) or epirubicin (1.13 mg/kg/wk). The compounds were intravenously injected once weekly for 7 consecutive wk at ADR-529: anthracycline ratios ranging from 5:1 to 20:1. These ratios covered the entire chemotherapeutic range in humans and allowed studying the chronic progressive cardiomyopathy in our rat model. Animals were observed for up to 35 wk to follow the time course of the well-characterized cardiomyopathy, which was evaluated through the well-established qualitative/quantitative morphological grading. It was clearly demonstrated in this rat model that ADR-529, at the ratios administered, provided ample cardioprotection for a duration of 35 wk, which corresponds to 25 yr of equivalent human time.
Bienvenu P., Caron L., Gasparutto D., and Kergonou JF (1992). Assessing and counteracting the prooxidant effects of anticancer drugs. In: Free Radicals and Aging, I Emerit and B Chance (eds). Birkhauser Verlag, Basel, pp. 257-262.
2.
Chacon E. and Acosta D. (1991). Mitochondrial regulation of superoxide by Ca2+: An alternate mechanism for the cardiotoxicity of doxorubicin. Toxicol. Appl. Pharmacol. 107: 117-128.
3.
Danesi R., Bernardini N., Macchiarini P., and Del Tacca M. (1990). Doxorubicin cardiotoxicity is reduced by pretreatment with the iron chelator ADR-529. Eur. J. Pharmacol. 183: 1703.
4.
Davies KJA and Doroshow JH (1986). Redox cycling of anthracyclines by cardiac mitochondria . J. Biol. Chem. 261: 3060-3067.
5.
Demant EJF and Jensen PK (1983). Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur. J. Biochem. 132: 551-556.
6.
Dunn OJ (1964). Multiple comparison using rank sums. Technometries3: 241.
7.
Earm YE, Ho WK, and So I. (1994). Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J. Mol. Cell. Cardiol. 26: 163-172.
8.
Fenoglio JJ (1983). The effects of drugs on the cardiovascular system . In: Cardiovascular Pathology, Vol. 2, MD Silver (ed). Churchill Livingstone , New York, pp. 1085-1107.
9.
Flandina C., Sanguedolce R., Rausa L., and D'Alessandro N. (1990). Ameliorative effects of ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res. Comm. Chem. Pathol. Pharmacol. 70: 259-272.
10.
Frank L. (1991). Oxidant injury to pulmonary endothelium. In: The Pulmonary Circulation and Acute Lung Injury, 2nd ed., SI Said (ed). Futura Publishing Co., Mount Kisco, NY, pp. 403-432.
11.
Gianni L., Corden BJ, and Myers CE (1983). The biochemical basis of anthracycline toxicity and antitumor activity. Rev. Biochem. Toxicol. 5: 1-82.
12.
Gutteridge JM (1984). Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. Biochem. Pharmacol. 33: 1725-1728.
13.
Hasinoff BB (1994). Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane. J. Pharmaceut. Sci.83: 64-67.
14.
Herman EH, Ardalan B., Bier C., Waravdekar V., and Krop S. (1981). Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters . Cancer Treat. Rep. 63: 89-92.
15.
Herman EH and Ferrans VJ (1981). Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+)-1,2-bis(3,5-diopiperazinyl-1-yl)propane (ICRF-187) . Cancer Res.41: 3436-3440.
16.
Herman EH and Ferrans VJ (1983). Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest . 49: 69-77.
17.
Herman EH and Ferrans VJ (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat. Rev. 17: 155-160.
18.
Herman EH, Ferrans VJ, Young RS, and Hamlin RL (1988). Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 48: 6918-6925.
19.
latropoulos MJ (1993). Comparative histokinetic and xenodynamic considerations in toxicity. In: Drug Toxicokinetics , PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 245-266.
20.
Monti E. and Sinha BK (1990). Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Comm.2: 145-149.
21.
Perkins WE, Schroeder RL, Carrano RA, and Imondi AR (1982). Effect of ICRF-187 on doxorubicin-induced myocardial effects ir the mouse and guinea pig. Br. J. Cancer46: 662-667.
22.
Podestà A., Della Torre P., Pinciroli G., Iatropoulos MJ, Brughera M. and Mazué G. (1994). Evaluation of 4'-iodo-4'-deoxydoxorubicininduced cardiotoxicity in two experimental rat models. Toxicol Pathol . 22: 68-71.
23.
Rajagopalan S., Politi PM, and Sinha BK (1988). Adriamycin-in duced free radical formation in the perfused rat heart: Implications for cardiotoxicity . Cancer Res. 48: 4766-4769.
24.
Robert J. (1993). Epirubicin. Drugs45(suppl.2): 20-30.
25.
Siegel S. (1956). Nonparametric Statistics for the Behavioral Sciences . McGraw-Hill, New York. 184 pp.
26.
Solcia E., Ballerini L., Bellini O., Magrini U., Bertazzoli C., Tosana G., Sala L., Balconi F., and Rallo F. (1981). Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori67: 461-472.
27.
Solem LE, Henry TR, and Wallace KB (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129: 214-222.
28.
Villani F., Galimberti M., Monti E., Cova D., Lanza E., Rozza-Dionigi A., Favalli L., and Poggi P. (1990). Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol. Appl. Pharmacol . 102: 292-299.
29.
Wadler S., Green MD, and Muggia FM (1986). Synergistic activity of doxorubicin and the bisdioxopiperazine(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF-187) against the murine sarcoma S180. Cancer Res.46 : 1176-1181.
